Disclosure Panels Details Page
Ovarian Cancer Panel - Disclosures as of 06/01/2010
|
Panel Member
(Spouse/Domestic Partner/Dependent) |
Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Employment/ Governing Board, Patent, Equity, or Royalty | Has Attended |
|---|---|---|---|---|---|
| Ronald Alvarez MD | None | Eli Lilly and Company GSK Ortho Biotech Products, L.P. |
None | None | ✔ |
| Deborah Armstrong MD | Agensys, Inc. Morphotek Inc. |
Abraxis Bioscience, Inc. Boehringer Ingelheim GmbH Eli Lilly and Company Genentech, Inc. Morphotek Inc. |
None | None | ✔ |
| Barry Boston MD | BEST | Bayer HealthCare Onyx Pharmaceuticals, Inc. Pfizer Inc. sanofi-aventis U.S. |
None | None | - |
| Robert Burger MD, FACOG, FACS | NA | NA | NA | NA | - |
| Lee-May Chen MD | AstraZeneca Pharmaceuticals LP | None | None | None | - |
| Larry Copeland MD | Eli Lilly and Company Genentech, Inc. Gynecologic Oncology Group |
Bayer HealthCare Celgene Corporation Eli Lilly and Company Precision Therapeutics, Inc. sanofi-aventis U.S. |
None | Gynecologic Oncology Group | ✔ |
| Marta Ann Crispens MD | None | None | None | None | ✔ |
| Mary Dwyer MS | None | None | None | None | ✔ |
| Lauren Gallagher | None | None | None | None | ✔ |
| David Gershenson MD | AstraZeneca Pharmaceuticals LP Genentech, Inc. Johnson & Johnson National Cancer Institute |
National Cancer Institute | None | Abbott Laboratories|Amgen Inc. |Eli Lilly and Company|Elsevier|Johnson & Johnson | ✔ |
| Heidi Gray MD | NA | NA | NA | NA | ✔ |
| Kristina Gregory MSN, RN | None | None | None | None | - |
| Perry Grigsby MD, MBA, MS | None | None | None | None | - |
| Laura Havrilesky MD | None | BD-TriPath Oncology Precision Therapeutics, Inc. |
None | None | - |
| Miranda Hughes PhD | None | None | None | Affymetrix|Myriad Genetic Laboratories, Inc.|Qiagen NV | ✔ |
| Carolyn Johnston MD | None | None | None | american cancer society-great lakes division|michigan cancer consortium | - |
| Shashikant Lele MD | None | None | None | None | ✔ |
| Ursula Matulonis MD | AstraZeneca Pharmaceuticals LP Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. |
Eisai Inc. Merck & Co., Inc. |
None | None | - |
| Joan McClure MS | None | None | None | None | ✔ |
| Robert Morgan MD, FACP | NIH-CTEP | None | None | Abbott Laboratories | ✔ |
| David O'Malley MD | Genentech, Inc. | KCI | None | None | ✔ |
| Richard Penson MD, MRCP | Berlex Inc. CuraGen Corporation Dara BioSciences, Inc. Eli Lilly and Company Endocyte Inc. Genentech, Inc. ImClone Systems Incorporated PDL BioPharma, Inc. |
None | None | None | ✔ |
| Steven Remmenga MD | None | None | None | None | ✔ |
| Paul Sabbatini MD | None | Boehringer Ingelheim GmbH Genentech, Inc. Johnson & Johnson |
None | None | ✔ |
| Russell Schilder MD | None | None | None | None | ✔ |
| Julian Schink | None | None | None | None | ✔ |
| Nelson Teng MD, PhD | NA | NA | NA | NA | - |
| Theresa Werner MD | None | None | None | None | ✔ |